Continuous Glucose Monitors (CGMs) represent a significant advancement in diabetes management, offering real-time glucose monitoring without the frequent finger sticks required by traditional methods. Despite these benefits, there are opportunities to improve everyday user experience. A potential alternative to current CGM systems is a long-term, implantable Continuous Blood Glucose Monitor (CBGM) that offers no on-body wearable components, minimal calibration requirements, and real-time continuous blood glucose readings. The goal of this study was to gather insights from endocrinologists to evaluate perceptions, drivers, and concerns related to this new approach. We used a mixed-methods approach, conducting an online survey and webcam interviews with U.S. endocrinologists who manage at least 50 patients with diabetes per month and regularly prescribe CGMs. Participants were introduced to the CBGM concept and asked about their level of interest in prescribing, what product features increase or reduce that interest, and how patient requests, clinical workflow, and long-term usability influence their decisions. This poster presents findings on what encourages and limits endocrinologists’ support for emerging CBGM technologies.
.jpg)
.png)
.png)